ABSTRACT Background/Purpose. Development of a humanized fluorophore-conjugated antibody that can improve contrast for fluorescence-guided oncologic surgeries. Methods. BxPC-3-GFP pancreatic cancer cells were injected into flanks of nude mice. Fragments of subcutaneous tumors were grafted onto the pancreatic tail of recipient mice to create orthotopic xenograft models of pancreatic cancer. After tumors developed for 4 weeks, a humanized anti-carcinoembryonic antigen antibody conjugated to an 800 nm near-infrared fluorescent dye (hM5A-IR800) was injected intravenously. Mice were imaged at 6, 12, 24, 48, and 72 h after injection. Results. Fluorescence imaging showed that hM5A-IR800 specifically localized to BxPC-3 human pancreatic cancer cells. The fluorescent probe localized to cell surfaces in vitro and specifically co-localized with green fluorescent protein-labeled tumors in an orthotopic pancreatic xenograft model in vivo. Serial imaging at specific time points showed peak signal intensity of the orthotopic pancreatic tumor at 48 h; this time point corresponded with a maximal tumor-to-background ratio (TBR) of 16.6 at 48 h.
Discussion. hM5A-IR800 was successfully able to specifically label orthotopic pancreatic tumors in situ. The longer wavelength allowed deeper tissue penetration, particularly in tumor areas covered by normal pancreatic parenchyma. The probe had expected kinetics for an antibody-fluorophore conjugate, with the peak signal intensity reached at 48 h. A clear tumor signal was observed with a TBR [ 5 at all time points, with high contrast (TBR of 16.6) at 48 h. Conclusion. hM5A-IR800 demonstrated excellent tumor localization and a very bright signal. It is a promising agent for future clinical fluorescence-guided surgery applications.
Pancreatic cancer is an aggressive malignancy with a poor survival rate and the only curative treatment is surgical resection with true negative margins; however, delineation of tumor margins is challenging in practice. Surgeons commonly use visual and tactile feedback, along with clinical judgment based on preoperative cross-sectional imaging, to determine the boundaries of resection; however, this is insufficient. As many as 80% of pancreatic resections are considered R1 (defined as the presence of cancer cells directly at, or \ 1 mm from, the margin) and this remains an independent determinant of postoperative outcome.
1,2 Fluorescence-image guidance is an approach that can be utilized within the operative field to enhance contrast and visualization of the neoplasm.
Current utilization of fluorescence navigation technology within the operating room has been limited to nonspecific dyes such as indocyanine green (ICG), and, as such, oncologic applications have been limited.
Conjugation of tumor-targeting antibodies to fluorophores confers specificity to the dye and can help surgeons visualize tumor, margins, and any satellite lesions in situ. Fluorescence-guided surgery (FGS) has been shown to significantly reduce the volume of residual cancer and extend disease-free and overall survival in a number of preclinical orthotopic mouse models of colon, pancreatic, breast, lung, brain, skin, and soft tissue cancers. [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] The human carcinoembryonic antigen (CEA), or CEA-CAM5, is an appealing target as it is a well-characterized tumor antigen. It is present in low levels during human embryonic development, absent in normal adult tissue, and highly expressed in a number of solid gastrointestinal malignancies. Our laboratory has pioneered the use of anti-CEA antibodies to target a fluorescence signal in orthotopic mouse models of pancreatic and colon cancers. We have transitioned from proof-of-concept studies using murine anti-CEA antibodies conjugated to fluorophores, to chimeric antibodies; 13, 14 however, even chimeric antibodies have been shown to induce the production of human antimouse antibodies. 15 In the present study, we used a humanized anti-CEA hT84.66-M5A (hM5A) monoclonal antibody (mAb) developed by Yazaki et al. 16 We chose to conjugate the antibody to an 800 nm near-infrared (NIR) fluorescent dye. Previous work in our laboratory has shown that the use of fluorophores in the NIR range decreases autofluorescence and background signal. 14 In this study, we show that hM5A-IR800 probes can successfully target human pancreatic cancer in situ using orthotopic xenograft mouse models, with useful kinetics and a favorable tumor-tobackground ratio (TBR).
METHODS

Tissue Culture
The human pancreatic cancer cell lines BxPC-3 (ATCC Ò CRL-1687 TM ), stably expressing green fluorescent protein (GFP), and MiaPACA-2 (ATCC Ò CRL-1420 TM ), expressing red fluorescent protein (RFP), were maintained in Roswell Park Memorial Institute 1640 (RPMI-1640) medium (Gibco-BRL, Grand Island, NY, USA). The medium was supplemented with 10% fetal calf serum (Hyclone Laboratories, Logan, UT, USA), 1% L-glutamine, and 1% penicillin/streptomycin (Gibco-BRL). The cells were incubated at 37°C in a 5% CO2 incubator.
Antibody Conjugation
The humanized M5A mAb was developed by grafting the complementarity-determining region of the murine anti-CEA antibody mT84.66 onto the humanized antip185HER2 antibody (trastuzumab) framework and expressed as previously described. 16 The purified hM5A antibody was conjugated with NHS-IRDye800CW (LI-COR Biosciences, Lincoln, NE, USA) at a tenfold molar excess of the esterified dye at room temperature for 1 h. Concentrations of the hM5A-IR800 conjugate were determined by absorbance 280 . The final concentration of antibody-dye conjugate was 5.7 mg/mL, with an average of six dye molecules per immunoglobulin G based on mass spectrometry.
Immunofluorescence Imaging of Pancreatic Cancer Cells
BxPC-3-GFP and MiaPaca-2-RFP cells were grown overnight on cover slips coated with 0.1% gelatin (5 9 10 5 cells per well). The cells were incubated with 200 nM of hM5A-IR800 for 1 h at 37°C. After washing, the cells were fixed with 4% formaldehyde (Fisher Scientific, Waltham, MA, USA) for 15 min, and stained with 300 nM DAPI (Fisher Scientific) for 5 min. The cover slips were mounted on slides with ProLong Gold antifade reagent (Life Technologies, Grand Island, NY, USA). Cells were imaged at 200 9 using a Nikon A1R Confocal laser microscope (Nikon Instruments, Melville, NY, USA).
Animal Care and Use
Immunocompromised nude nu/fox mice were maintained in a barrier facility on high-efficiency particulate air (HEPA)-filtered racks at the laboratories of AntiCancer, Inc. Mice were maintained ad lib on an autoclaved laboratory rodent diet (Teckland LM-485; Western Research Products, Orange, CA, USA) and kept on a 12-h light/12-h dark cycle. All surgical procedures and intravital imaging were performed with the animals anesthetized by intramuscular injection of an anesthetic cocktail composed of ketamine 100 mg/kg (MWI Animal Health, Boise, ID, USA), xylazine 10 mg/kg (VWR, Brisbane, CA, USA), and acepromazine 3 mg/kg (Sigma, St Louis, MO, USA). All animal studies were conducted in accordance with the principles and procedures outlined in the National Institutes of Health (NIH) Guide for the Care and Use of Animals under PHS Assurance Number A3873-1.
Surgical Orthotopic Implantation and In vivo studies
BxPC-3-GFP pancreatic cancer cells (1 9 10 6 cells per animal) were injected subcutaneously into the flank of nude mice. The tumors were allowed to grow for 4 weeks or until 7-10 mm in size. The tumors were harvested and 2 mm 3 fragments were implanted into the pancreatic tail of recipient nude mice using surgical orthotopic implantation to create orthotopic models of pancreatic cancer. [17] [18] [19] After the tumors developed for 2 weeks, 75 lg of hM5A-IR800 was injected via the tail vein. Three mice per time point were sacrificed and imaged at 6, 12, 24, 48, 72, and 96 h after injection using the Maestro CRI imaging system (Perkin Elmer, Waltham, MA, USA). The images were acquired with the GFP filter set (excitation 488 nm, emission 510 nm) and the IR800 filter set (excitation 778 nm, emission 800 nm). Fluorescence intensity was quantified at the skin and tumor using the Maestro CRI software. Fluorescence intensity was adjusted for background signal at the skin by subtracting the intensity value at an area of adjacent skin to the intensity value at the tumor. TBR was calculated by dividing the intensity value at an area of adjacent skin to the intensity value at the tumor.
RESULTS
Staining with hM5A-IR800 showed that the fluorescent antibody bound the high CEA-expressing BxPC-3-GFP human pancreatic cancer cell line in-vitro (Fig. 1a) . Merged images of the GFP and hM5A-IR800 channel show the fluorescent antibody localized at cell surfaces and within cells. Staining with hM5A-IR800 showed little to no antibody binding to the low CEA-expressing MiaPaCa-2-RFP human pancreatic cancer cells (Fig. 1b) . Merged images of the RFP and hM5A-IR800 channel show poor antibody localization.
Non-invasive imaging of mice at 48 h showed that a fluorescence signal from the BxPC-3 pancreatic tumor was visible through the skin, abdominal wall soft tissue, and musculature (Fig. 2a, b) . When comparing the GFP and LICOR800 channels, the NIR wavelength demonstrates a stronger tumor signal through the tissue layers. In the same mouse, after laparotomy, the tumors are again visible in the GFP and LICOR-IR800 channels (Fig. 2c, d ). The areas labeled by hM5A-IR800 clearly overlap with the GFPtagged tumor. Magnified views show that the fluorescence signal from GFP can be dampened by the overlying pancreatic parenchyma and vasculature (Fig. 2e, f) , in contrast to the IR800 signal where the fluorescence signal was clearly detectable through overlying tissue (Fig. 2b, bottom  panels) .
To determine the pharmacokinetics of this antibody-dye conjugate, mice underwent intravital imaging at 6, 12, 24, 48, 72, and 96 h after injection (the results are summarized in Fig. 3a) . Peak fluorescence signal was obtained at 48 h after initial injection. The mean fluorescence intensity value at 48 h was 1695 counts, compared with 1186 counts at 6 h, 1204 counts at 12 h, 1428 counts at 24 h, 1046 counts at 72 h, and 1022 counts at 96 h. There was a high fluorescence signal in the liver from the earliest time point at 6 h but this signal rapidly decreased after 12 h. The signal at the liver was as follows: 6 h (1050 counts), 12 h (954 counts), 24 h (493 counts), 48 h (2269 counts), 72 h (111 counts), and 96 h (113 counts). There was also some mild background fluorescence signal at the skin and the highest signals were within the first 24-48 h, with the signal decreasing steadily thereafter. The signal at the skin was as follows: 6 h (194 counts), 12 h (146 counts), 24 h (170 counts), 48 h (103 counts), 72 h (69 counts), and 96 h (85 counts).
The time of peak signal intensity correlated with the maximal TBR at 48 h (TBR = 16.6), as shown in Fig. 3b Serial intravital images are displayed in Fig. 4 . All images demonstrate a fluorescence signal targeted to the tumor at the IR800 wavelength (blue asterisks). The images show additional background noise at the liver (green arrows) and bladder (yellow arrowheads) that steadily decreases over time.
DISCUSSION
In the present report, we demonstrate the feasibility, distribution, kinetics, and advantages of using a humanized anti-CEA antibody conjugated to an NIR IR800 fluorophore for in situ tumor-specific labeling of orthotopic human pancreatic xenografts in nude mice Fig. 5 .
The BxPC-3 tumor was selected as a high CEA-expressing human pancreatic cancer cell line, as previously shown by flow cytometry. 20, 21 Cellular microscopy confirmed binding of the fluorescent hM5A-IR800 antibody to this cell line in-vitro and its subcellular localization at the surface membrane, which is consistent with its known status as a cell surface glycoprotein. hM5A-IR800 is a probe that binds specifically to CEA as it did not demonstrate any binding at the same concentration in a low CEA- chimeric antibodies where nearly 30% of patients developed human anti-chimera antibodies, no human anti-human antibody immunological response has thus far been detected in current studies using humanized M5A (unpublished data, Dr P. Yazaki). In the present study, humanized M5A conjugated to an NIR-fluorophore becomes a highly specific probe for fluorescence in situ tumor labeling.
In-vivo studies highlight the improvements in visualization using an NIR wavelength. The fluorescence signal of GFP is limited with increasing tissue depth due to a relatively short emission wavelength. The use of NIR fluorophores improves tissue penetration with decreased background noise. LICOR-IRDye800CW is a promising dye for future clinical use as it is a biocompatible fluorophore in the NIR spectrum and it has been validated in several phase I/II clinical trials for fluorescence-guided surgery of head and neck cancer (NCT02415881, NCT01987375, NCT02736578). 25, 26 Additionally, the emission and absorption spectra of LICOR-IRDye800CW overlap with that of ICG. A number of FDA-approved imaging platforms exist for imaging ICG and the spectral overlap permits visualization of IRDye800-labeled probes. 27, 28 Time-course studies showed a tumor-specific signal present as early as 6 h; however, non-specific background noise was present over the liver, bladder, and skin that decreased over time as the tumor signal increased. Despite the background noise, there was an adequate tumor-tobackground signal at all time points evaluated. A nonspecific background signal over the skin and soft tissue is likely attributable to the circulating probe not yet bound to the tumor or eliminated. This skin and soft tissue signal is minor and will not pose an issue for this construct in clinical surgical use. The signal over the bladder is likely due to a degree of proteolytic degradation and renal elimination of resulting peptides and fluorophore. As most patients undergoing major oncologic surgery are catheterized, this will not likely be an issue in the operative field; however there is significant accumulation of the antibodydye conjugate at the liver beyond expected for known antibody hepatic accumulation. 29, 30 This liver signal may be due to additional hydrophobicity from LICORIRDye800CW. This signal could potentially be an issue as it can potentially mask CEA-positive hepatic malignancies or CEA-positive colorectal liver metastases. Despite the initial fluorescence at the liver, the signal rapidly decreases after 12 h and returns close to baseline near 48 h and beyond. The addition of polyethylene glycol (PEG) groups or attachments of the fluorophore in a conformation that may mask the hydrophobic moieties could be approaches to improve this issue, which will be addressed in future work. 31 
CONCLUSIONS
Humanized anti-CEA-800 tumor-specific dye specifically labeled orthotopically implanted pancreatic cancer xenografts, and the dye successfully co-localized with GFP-tagged tumor cells. The longer wavelength allowed for deeper tissue penetration, particularly in areas of the tumor covered by normal pancreatic parenchyma. Humanized anti-CEA antibody conjugated to a radiolabeling agent is undergoing phase I/II trials. IRDye800CW has also been in a number of phase I/II trials for FGS of head and neck cancers. Humanized anti-CEA conjugated with the IR-800 dye is a promising agent for future clinical FGS applications.
